Secondary Navigation Menu

Audience Switcher Modal

Country and Audience Choose Modal

Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.

Scientific Congress Publications

Supported by Bayer Pharmaceuticals

WCLC 2026

Molecular Landscape of Acquired Resistance to Sevabertinib in HER2-mutant NSCLC: Exploratory Biomarker Analysis of SOHO-01
Date/Time:
September 12-15, 2026 | 11:25 AM – 11:30 AM
Session:
Closing The Gaps In Driver Altered NSCLC: Moving Beyond Current Boundaries
Type:
Mini Oral
Presenting Author:
Xiuning Le
View the Abstract
Back to Oncology

© 2026 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.

Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.

Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.

For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/

PP-GEN-ALL-0014-1